Introduction
Daring tho early studies of factor IX containing concentrates the concept of throm bogenicity as a potential hazard was clcarly recognised (M6nachc et al. 1959) , and although in most subsequent reports on tho clinical uso of such preparations this problem did not appear to arise (Bidwell et al. 19G7; Gilchrist et al. 1969; Diko et al. 1972; Bruning et al. 1971; Josso 1970; Nilsson ct al. 1971) , in others there seemed little doubt that thrombogcnicity was a real hazard (Tullis and Breen 1970; Kasper 1973; Steinberg and Drciling 1973; Edson 1974; Marchcsi and Burncj' 1974) .
In 1967 n factor IX concentratc (P.P.S.B.) was first prepared in Scotland using tho method described by Soulier ct al. (1974) , using EDTA plasma. This lias been widely used in congenital and acquired factor IX dcficicncy with no reports received of thrombogcnicity. In 1971 further protein fractionation developments led to the introduction of DEFIX, a conccntrato containing factors II, IX and X prepared from citratcd, factor VIII depleted plasma (Middleton ct al. 1972 ). This product has been distributed routinely for tho management of haemophilia B patients in Scotland since that time, again without reports of thrombogcnicity. More recent developments have concerned the further purification of DEFIX, using polyethylene glycol PEG 4000 in order to produce a more potent conccntrato and possibly carrying less risk of transmitting seruin hepatitis (Johnson ct al. 1973 ). This PEG concentrate (PEG-IX) has not vet been distributed for routine clinical use, but its development prompted us to consider whether efforts designed to increase purity might lead to a final product which was potentially thrombogcnic. In this study an in vivo model was used and the dog selected as its size permitted serial blood sampling over prolonged periods of time. Tho factor IX concentrates currently prepared in the Scottisli National Protein Fractionation Centre arc summarised in Tablo 1.
Materials and Methods
Healthy femalo mongrel or Collio dogs weighing 15-25 kg, previously fed ad-lib, wcro used. Anacsthctic induction was obtained using intravenous pentobarbitone sodium. Their brachial (infusion) and femoral (blood sampling) veins wcro cannulatcd. Tho patcncy of these cannulao was maintained by an infusion of 5% dextrose. Tho urinary blad der was cnthcteriscd with a sclf-rctaining Foley catheter and urine collected at lOminuto intervals. Fulso rates wcro monitored using on electrocardiograph. Not less than GO mi nutes after the Foley catheter had been inserted (tho absoluto timo depending on tho steady urine flow) tho infusion schedule was begun by control period (50 ml isotonic salino) * Task Force Report (150) an . The results of the citrate-saline infusion arc summarised in Fig. 1 . Xo significant changes in tlio parameters measured were recorded during tlio 240 minute observation period witli the cxccption of a small but consistent rise in serum F.D.P. in all animals. Tho results of infusions of normal plasma, albumin, fibrinogen, gammaglobulin, DEFIX (150 n/Ivg) and PJiG-IX (50 u/Kg) were not significantly different from the citrate-saline controls. SuDDlied bv The British Library -"The world's knowledge"
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2. Thrombin During tlio infusion of thrombin ample laboratory evidence of disseminated intra vascular coagulation (DIC) was observed (Fig. 2) . There was a profound fall in the platelet count, fibrinogen and a rise in the partial thromboplastin times and serum F.D.P. Severe oliguria was also associated with the infusion of thrombin. 
P.P.S.B.
The results of the infusions of P.P.S.B. (150 u/Kg) into three dogs arc summarised in Fig. 3 . Sixty minutes after tho infusion had been terminated there was a fall in the platelet count in two dogs, which returned spontaneous]}-towards tho prc-infusion values. Satisfactory interpretation of fibrinogen assays was not possible in these studios; after thawing tho frozen plasma it was noted that a significant number of post-infusion samples had clotted, making fibrinogen estimations by tlio Ellis and Stransky (1961) method impossible. Tho partial thromboplastin time lengthened . slightly during tho infusion and this was assumed to bo related to the heparin present in our preparations of P.P.S.B. The results of tho serum F.D.P. and cthanol gelation tests in conjunction with evidence of spontaneous clotting of fibrinogen during freeze/ thawing was taken as evidence oflow grade DIC in all tlireo dogs. It was noted that this phenomenon did not occur during the infusion but was delayed in onset. In all dogs laboratory evidence of DIC was associated with a modest-reduction in urine output.
PEG-IX (500)
The results of the infusion studies of PEG-IX at a dose of 500 units per Kg are summarised in Fig. 4 . All three dogs showed a marked fall in platelet count, which occurred between 30-G0 minutes after the infusion had been completed. Complete defibrination was also observed in all dogs but its onset again occurred some time after the termination of the infusion. The partial thromboplastin time lengthened slightly during the infusion, presumably due to the added heparin in this preparation; it then shortened, but was followed by a dramatic lengthening due to tho developing defibrination. The seruin F.D.P. and ethanol gelation data was also consistent with DIC in all dogs. There was a period of severe oliguria which coincided with the episode of DIC.
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Discussion
All the factor IX containing concentrates used in this study had passed the then existing 'in house' in vitro thrombogcnicity tests, based on the cffccts of the conccn trato on the clotting time of purified fibrinogen and the recalcification time of normal citrnted plasma. A concentrate containing more than 0.1 U thrombin per ml was considered unsuitable for clinical use. The batches studied on two of these concentrates (P.P.S.B. and DEFIX) had been given to mail}' patients with no untoward effects reported.
The results of our investigation clearly demonstrated that in the very high doses used the particular batches of human P.P.S.B. and PEG-IX given to clogs were associated with low grado and extensive DIC, respectively. The evidence in favour of this conclusion was largely laboratory in origin but histology performed, on a separate run, of the kidney removed at tho height of tho DIC episode following PEG-IX (500 u/Kg) revealed widespread intra-renal microcirculatory thrombosis (Davidson 1975) . This finding wo presumed was the cause of the reversible renal failure observed. That this phenomenon was closcly related to the administration of factor IX containing concentrates was evident by the absence of significant changes following the infusion of human plasma, fibrinogen, albumin and gammaglobulin.
Of particular interest was the observation that a considerable time elapsed (at least 30 minutes) after the infusion of both P.P.S.B. and PEG-IX before DIC was detected. This finding is in contrast to the report of Triantophyllopoulos (1972) who observed DIC arising during the infusion of prothrombin complex. However, these studies were conducted on rabbits using conccntratcs prepared bj' a different method from those used in Scotland. At the present time wo have concludcd that the delayed DIC response in our studies must be related to the gradual generation of thrombin in vivo, but beyond this there is no cvidencc on which to base a further h} -pothcsis. The clinical significance of these canino observations must also remain in doubt. The doses used have little clinical rclcvance, as that given to patients is of the order of 30 u/Ivg; quantities which wo are certain would have no thrombogcnic clfccts in terms of DIC in dogs. However, they might be relevant in tho contcxt of managing patients with factor IX inhibitors or neonates and patients with liver disease. For this reason, simple in vitro techniques are currently being developed designed to assess the thrombogcnic potential of different factor IX conccntrato batches and laboratory observations arc in hand on patients receiving these concentrates as part of their medical management.
Resume
La thrombogdnicite de plusicurs concentres do factcur IX obtenus par difTercntes methodes, adsorption sur phosphate calcique, chromatographic sur DEAE-ccllulosc suivic ou non de precipitation par le polyethylene glycol a etc essayee sur I D chien. Bien qu'ayant passe les tests do thrombog6nicit6 in vitro, deux types de preparation PPSB ct PEG-IX ont provoquo h dose elevce unc CID modcrcc pour la premiere ct grave pour la deuxicmc preparation.
Zusamnicnfassung
Die Thrombogenizitat mchrcrcr Faktor-IX-Konzentrate, init vcrschicdcnen Methoden-Adsorption auf Kalziumpliosphat, DEAE-Zcllulosc-Chromatographie mit und ohncPEG-Fallung-gewonnen, wurdc beim Hund gepriift. Obschon allcPraparatc in vitro negative Rcsultato gezcigt hatten, provozicrten hoclulosicrtc Prnparate, PPSB und PEG-IX, cino lcichto rcsp. starko DIG beim Hund.
